Modulation of angiogenesis by dithiolethione‐modified NSAIDs and valproic acid
暂无分享,去创建一个
T. Moody | A. Sparatore | D. Wink | L. Ridnour | D. Roberts | R. Ramchandran | A. Sowers | G. Yeh | P. Soldato | J. Isenberg | Y. Jia | L. Field
[1] A. Sparatore,et al. Anti-inflammatory and gastrointestinal effects of a novel diclofenac derivative. , 2007, Free radical biology & medicine.
[2] J. Wallace,et al. 5-Amino-2-hydroxybenzoic Acid 4-(5-Thioxo-5H-[1,2]dithiol-3yl)-phenyl Ester (ATB-429), a Hydrogen Sulfide-Releasing Derivative of Mesalamine, Exerts Antinociceptive Effects in a Model of Postinflammatory Hypersensitivity , 2006, Journal of Pharmacology and Experimental Therapeutics.
[3] S. Flis,et al. Antiangiogenic effect of sulindac sulfide could be secondary to induction of apoptosis and cell cycle arrest. , 2006, Anticancer research.
[4] Jeannette Bigler,et al. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics , 2006, Nature Reviews Cancer.
[5] Napoleone Ferrara,et al. Angiogenesis as a therapeutic target , 2005, Nature.
[6] Peter Carmeliet,et al. Angiogenesis in life, disease and medicine , 2005, Nature.
[7] Y. Cao,et al. Tumor angiogenesis and therapy. , 2005, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[8] D. Wink,et al. Thrombospondin-1 inhibits endothelial cell responses to nitric oxide in a cGMP-dependent manner. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[9] Y. Surh,et al. Nrf2 as a novel molecular target for chemoprevention. , 2005, Cancer letters.
[10] S. Chaufour,et al. Hsp27 consolidates intracellular redox homeostasis by upholding glutathione in its reduced form and by decreasing iron intracellular levels. , 2005, Antioxidants & redox signaling.
[11] H. Waldmann,et al. Inhibition of Angiogenesis‐Relevant Receptor Tyrosine Kinases by Sulindac Analogues , 2005, Chembiochem : a European journal of chemical biology.
[12] H. Cai,et al. Role of CaMKII in hydrogen peroxide activation of ERK1/2, p38 MAPK, HSP27 and actin reorganization in endothelial cells , 2004, FEBS letters.
[13] Samuel A. Santoro,et al. Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through α2β1 integrin , 2004, The Journal of cell biology.
[14] C. Harris,et al. Hypoxic inducible factor 1α, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[15] Peter Carmeliet,et al. Manipulating angiogenesis in medicine , 2004, Journal of internal medicine.
[16] S. Loitsch,et al. Modulation of angiogenesis-related protein synthesis by valproic acid. , 2004, Biochemical and biophysical research communications.
[17] S. Gately,et al. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. , 2004, Seminars in oncology.
[18] R. Busse,et al. Valproic acid inhibits angiogenesis in vitro and in vivo. , 2004, Molecular pharmacology.
[19] S. Libutti,et al. Angiogenesis inhibitors target the endothelial cell cytoskeleton through altered regulation of heat shock protein 27 and cofilin. , 2003, Cancer research.
[20] P. O'dwyer,et al. Role of the AP-1 element and redox factor-1 (Ref-1) in mediating transcriptional induction of DT-diaphorase gene expression by oltipraz: a target for chemoprevention. , 2003, Biochemical pharmacology.
[21] J. Spławiński,et al. Anti-angiogenic and apoptotic effects of metabolites of sulindac on chick embryo chorioallantoic membrane. , 2003, Hybridoma and hybridomics.
[22] B. Weinstein,et al. In vivo imaging of embryonic vascular development using transgenic zebrafish. , 2002, Developmental biology.
[23] V. Steele,et al. A quantitative angiogenesis model for efficacy testing of chemopreventive agents. , 2001, Anticancer research.
[24] M. Kwak,et al. Role of phase 2 enzyme induction in chemoprotection by dithiolethiones. , 2001, Mutation research.
[25] A. Logan,et al. Angiogenesis , 1993, The Lancet.
[26] B. Böttcher,et al. ber Trithione, V. Mitteil. Notiz ber einige neue Trithione) , 1951 .
[27] H. Verheul,et al. Angiogenesis inhibitors: what is the clinical future? , 2005, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.
[28] B. Ruggeri,et al. The chemopreventive agent oltipraz possesses potent antiangiogenic activity in vitro, ex vivo, and in vivo and inhibits tumor xenograft growth. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[29] M. Christen,et al. Anethole dithiolethione regulates oxidant-induced tyrosine kinase activation in endothelial cells. , 2000, Antioxidants & redox signaling.
[30] T. Kensler,et al. Chemoprotection by Organosulfur Inducers of Phase 2 Enzymes: Dithiolethiones and Dithiins , 2000, Drug metabolism and drug interactions.
[31] J. Landry,et al. Regulation of actin dynamics by stress-activated protein kinase 2 (SAPK2)-dependent phosphorylation of heat-shock protein of 27 kDa (Hsp27). , 1999, Biochemical Society symposium.
[32] K. Helzlsouer,et al. Mechanisms of chemoprotection by oltipraz , 1992, Journal of cellular biochemistry. Supplement.